TRL 7–8 Scale-ready
15 Years IIT Hyderabad R&D
2 Platform Patents

Nano molecular diagnostics in <30 mins.

Femtomolar molecular insight across RNA, DNA and protein biomarkers—all from one pocket-sized reader. Anywhere. Anytime.

BioKubit Handheld Diagnostic Device

1,000×

Sensitivity vs. ELISA/qPCR

<30mins

Result delivery

<5µL

Sample volume

94.2%

Reported accuracy

About us

Institutional strength & validation.

01

Platform IP

Two reported patents securing the core detector and nano-biosensor architecture.

02

IIT Hyderabad

Backed by 12 PhD researchers and a massive 15-year institutional R&D foundation.

03

Clinical validation

ICMR-CCMB validation including a rigorously reported 94.2% clinical accuracy.

04

Reusable architecture

A single reader unit designed to support infinite new panels purely through cartridge changes.

Founders & Partners

Science, genomics and scale.

Ashish Kumar

Ashish Kumar

Genomics & AI

Karolinska Institute / Oxford-trained specialist leading global partnerships.

Shiv Govind Singh

Shiv Govind Singh

Nano-biosensors

IIT Hyderabad pioneer leading core R&D, IP and manufacturing scale-up.

Amit Satpathy

Amit Satpathy

Scale & Partnerships

Vodafone / Reliance veteran executing commercial strategy and rollout.

IIT Hyderabad

Institutional Partner

Embedded researchers, platform patents and deep scientific foundations.

Microfluidic Biosensor Chip
The technology

One reader.
Unlimited biomarkers.

Keep the detector. Change the “fishing hook” cartridge to target a new biomarker—without re-engineering the reader architecture.

01

Cardiac Panel

Trop-X · NTProBNP

02

Infectious Disease

RNA · DNA panels

03

Skin & Beauty

18+ biomarkers profiling

04

Food & Environment

Pathogen · water panels

Market potential

One platform. Many markets.

Swap the cartridge to serve new needs across healthcare, diagnostics, beauty and future self-care sectors globally.

01 · Healthcare

Hospitals & government POC

Cardiac and respiratory panels deployed from emergency departments to community scale screening initiatives.

$15.3B addressable market
02 · Personal care

Beauty & skincare

Molecular skin profiling with 18+ biomarkers driving highly personalized, science-backed consumer experiences.

$12–30B opportunity
03 · Partnerships

Diagnostic device leaders

License our nano-core architecture to upgrade existing systems with molecular sensitivity.

1,000× sensitivity upgrade
04 · Future scale

At-home self-care

A future direct-to-consumer platform with high-margin recurring cartridge potential after partner-led scale.

500M+ households
Partner solutions

Built around your deployment.

Choose a pilot, a platform license or a white-label program.

Hospitals & clinic networks

Deploy X-Home™ at scale. Use multiplex cardiac panels in emergency, cardiology and pathology settings.

Government authorities

Build screening programs. Explore cardiac screening, infectious-disease surveillance and rural health.

Diagnostic leaders

License the platform. Integrate with existing point-of-care readers and jointly validate new biomarkers.

Beauty & skincare

Offer molecular profiling. Develop white-label testing around 18+ skin biomarkers.

15-year roadmap

From nanomaterials to handheld diagnostics.

2010–14

Nano-material & Bio-conjugation

Foundational research at IIT Hyderabad and selective biomarker capture protocols.

2015–18

Prototype & Multiplexing

Femtomolar sensitivity proof of concept and multiple biomarkers on one platform.

2019–22

Patents & Clinical Validation

Detector architecture IP filed. Reported 94.2% accuracy in COVID RNA and Cardiac panels.

2023–24

X-Home™ & TRL 7-8

Handheld reader finalized, robotic GMP process secured. Prepared for pilots and licensing.

Competitive edge

Molecular depth. Point-of-care speed.

Approach Molecular readout Format & sample Panel flexibility
BioKubit X-Home™ RNA, DNA & protein Handheld · <5 µL · <30 mins Multiplex · swappable cartridge
Surface imaging Visual surface signals Imaging equipment Visual features
Lab genomics / ELISA Molecular Laboratory workflow Defined assays
Investment opportunity

$5M Seed Round

Funding hospital pilots, government POC deployments, and device licensing partnerships. With a clear structural path to a massive $1B+ exit projection.

Discuss the opportunity
Modern biomedical research laboratory
Partner with us

Let’s build the next deployment.

Outline a hospital deployment, government POC, licensing, beauty partnership or investor conversation.

Pilot-ready in months

IIT Hyderabad incubated · ICMR-CCMB validated · TRL 7–8